With a modular and data-driven approach, our pipeline emphasizes small molecules and biologics, progressing from early discovery to robust experimental validation. By integrating in silico design with state-of-the-art in vitro assays, we ensure rapid iteration and de-risking of candidates. Our agile pipeline strategy allows for efficient prioritization and advancement of programs with the highest therapeutic potential, positioning us at the forefront of computationally enhanced drug discovery.